Biotalys and Novozymes announce the success of Evoca™

Ghent, BELGIUM and Copenhagen, DENMARK, Oct. 24, 2022 (GLOBE NEWSWIRE) — Biotalys (Euronext – BTLS)an agricultural technology (AgTech) company protecting crops and food with protein-based biocontrol solutions, and NOTovozymes, a global leader in biotechnology solutions, including Ag biologics, today announced the successful completion of the feasibility study for Evoca™*, Biotalys’ first proprietary biocontrol product candidate. Novozymes has obtained proof of concept for a new manufacturing process that offers significant potential advantages in terms of cost of goods and scale, thereby expanding the commercial potential of Evoca as a novel biofungicide.

“Thanks to its cutting-edge expertise in protein fermentation, Novozymes was able to further increase the production efficiency of Evoca”, said Patrice Sellès, CEO of Biotalys. “We will now work on a deeper partnership with Novozymes and explore strategic supply and commercialization agreements for the future generation of Evoca while continuing our ongoing internal development activities.”

Evoca is Biotalys’ first innovative protein-based biofungicide developed on the company’s AGROBODY Foundry™ platform. This technological platform enables Biotalys to discover and develop new biological food protection solutions combining high efficiency, regularity and safety, with new modes of action to combat resistance. Evoca helps sustainably control economically important fungal diseases such as Botrytis and powdery mildew in fruits and vegetables. Demonstrate strong performance over 600+ independent and business-oriented field and greenhouse trials across multiple regions, pathogens and crops, Evoca is expected to gain U.S. Environmental Protection Agency (EPA) approval in early 2023.

Since entering into a partnership in June 2022, Novozymes has explored additional avenues for scale-up and production of Evoca’s bioactive protein using additional production hosts to those currently used by Biotalys. Novozymes has discovered new ways to increase production and efficiency that could help Biotalys expand the market reach of Evoca, both in the preliminary US and European fruit and vegetable markets currently in the commercialization plan, as well than in other geographies, cultures and diseases. Subject to confirmation of commercial scaling, field trial performance and regulatory procedures, these results may help reduce the time to a commercially attractive version of Evoca.

“The results of this feasibility study with Biotalys will help pave the way for more profitable and sustainable solutions for growers around the world,” noted Thomas Batchelor, Vice President, Agricultural marketing and Novozymes strategy. “Now one step closer to large-scale production, Biotalys and Novozymes have successfully collaborated to provide industry and growers with new ways to safely control harmful pests and diseases and achieve our common goal. to provide highly efficient solutions so that producers can sustainably feed the world. ”

Having successfully completed this key milestone, the two companies are now entering the next phase of their partnership and will explore strategic supply and commercialization agreements for the next generation of Evoca. Novozymes and Biotalys will also explore R&D collaboration beyond Evoca to address the need for effective and more sustainable protein-based biocontrols in new markets and indications through Novozymes’ solutions portfolio and Biotalys’ product candidate pipeline. .

* Evoca™: recording pendingration. This product is currently not registered for sale or use in the United Statesthe European Union, or elsewhere and is not offered for sale.

About Biotalys

Biotalys is an agricultural technology (AgTech) company protecting crops and food with proprietary protein-based biocontrol solutions and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safe food supply. Based on its novel AGROBODY™ technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to control major crop pests and diseases across the entire value chain, from floor to plate. Biotalys was founded in 2013 as a spin-off from VIB (Flanders Institute for Biotechnology) and has been listed on Euronext Brussels since July 2021. The company is based in the biotech cluster of Ghent, Belgium. More information can be found at www.biotalys.com.

For more information, please contact

Toon Musschoot, Head of IR & Communication
T: +32 (0)9 274 54 00
E: [email protected]

About Novozymes

Novozymes is the world leader in biological solutions. Together with our customers, partners and the global community, we improve industrial performance while conserving the planet’s resources and helping to build better lives. As the world’s largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, lower temperature washing, energy-efficient production, renewable fuels and many other benefits that we rely on today and in the future. We call it Rethinking Tomorrow. www.novozymes.com

NASDAQ OMX: NZYM-B • 6,500 employees • Turnover of DKK 15 billion • Over 30 sectors • Over 700 products

Media Relations

Lina Danstrup | Media Relations Manager | Telephone: +45 30 77 05 52 | [email protected]

Investor Relations
Tobias Bjorklund | Head of Investor Relations | Phone: +45 30 77 86 82 | [email protected]

Important Notice

This announcement contains statements that are, or could be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “aim”, “believe”, “estimate”, “anticipate”, “expect”, “intend”, ‘may’, ‘will’, ‘plan’, ‘continue’, ‘ongoing’, ‘possible’, ‘predict’, ‘plan’, ‘target’, ‘seek’, ‘would’ or ‘should’, and contain statements made by the company regarding the expected results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that none of these forward-looking statements offer guarantees of future performance. The actual results of Biotalys may differ materially from those predicted by the forward-looking statements. Biotalys does not undertake to publish any updates or adjustments to these forward-looking statements, except as required by law.

Comments are closed.